Genovefa A. Papanicolaou
Experienced in Methicillin-Resistant Staphylococcus Aureus (MRSA)

Dr. Genovefa A. Papanicolaou

Infectious Disease
Memorial Infectious Disease Group
1275 York Ave, 
New York, NY 
Offers Telehealth
33 Years of Experience
Experienced in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Memorial Infectious Disease Group
1275 York Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Genovefa Papanicolaou is an Infectious Disease provider in New York, New York. Dr. Papanicolaou has been practicing medicine for over 33 years and is rated as an Experienced provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). Her top areas of expertise are Cytomegalovirus Infection, Sepsis, Cytomegalic Inclusion Disease, and Pneumonia.

Her clinical research consists of co-authoring 134 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Infectious Disease
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

MEMORIAL INFECTIOUS DISEASE GROUP
1275 York Ave, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
Enrollment Status: Terminated
Publish Date: July 24, 2023
Intervention Type: Drug
Study Drug: Casirivimab+Imdevimab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Enrollment Status: No_longer_available
Publish Date: March 14, 2022
Intervention Type: Drug
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Enrollment Status: Terminated
Publish Date: January 25, 2021
Intervention Type: Other, Drug
Study Phase: Phase 2
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
View 5 Less Clinical Trials

134 Total Publications

Corrigendum to 'American Society for Transplantation and Cellular Therapy Series #10: Management of Parainfluenza and Human Metapneumovirus Infections in Hematopoietic Cell Transplantation and Cellular Therapy Recipients' [Transplantation and Cellular Therapy 31 (2025) 624-638/ https://doi.org/10.1016/j.jtct.2025.06.016].
Corrigendum to 'American Society for Transplantation and Cellular Therapy Series #10: Management of Parainfluenza and Human Metapneumovirus Infections in Hematopoietic Cell Transplantation and Cellular Therapy Recipients' [Transplantation and Cellular Therapy 31 (2025) 624-638/ https://doi.org/10.1016/j.jtct.2025.06.016].
Journal: Transplantation and cellular therapy
Published: October 18, 2025
Similar Doctors
Keith S. Kaye
Elite in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Keith S. Kaye
Infectious Disease
Elite in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Keith S. Kaye
Infectious Disease

Rutgers Health-Rwj Scleroderma Program

125 Paterson St, 
New Brunswick, NJ 
 (31.9 miles away)
732-235-7060
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Keith Kaye is an Infectious Disease provider in New Brunswick, New Jersey. Dr. Kaye is rated as a Distinguished provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). His top areas of expertise are Methicillin-Resistant Staphylococcus Aureus (MRSA), Pneumonia, Hospital-Acquired Pneumonia, Sepsis, and Hip Resurfacing. Dr. Kaye is currently accepting new patients.

Anne-catrin C. Uhlemann
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Anne-catrin C. Uhlemann
Infectious Disease
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Anne-catrin C. Uhlemann
Infectious Disease

Trustees Of Columbia University In The City Of New York

622 W 168th St, 
New York, NY 
 (5.4 miles away)
212-305-9876
Languages Spoken:
English
See accepted insurances

Anne-catrin Uhlemann is an Infectious Disease provider in New York, New York. Dr. Uhlemann is rated as an Advanced provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). Her top areas of expertise are Methicillin-Resistant Staphylococcus Aureus (MRSA), COVID-19, Sepsis, and Severe Acute Respiratory Syndrome (SARS).

Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Bo Shopsin
Infectious Disease
Distinguished in Methicillin-Resistant Staphylococcus Aureus (MRSA)
Dr. Bo Shopsin
Infectious Disease

New York University

560 1st Ave, 
New York, NY 
 (1.8 miles away)
212-263-7300
Languages Spoken:
English

Bo Shopsin is an Infectious Disease provider in New York, New York. Dr. Shopsin is rated as an Advanced provider by MediFind in the treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA). His top areas of expertise are Methicillin-Resistant Staphylococcus Aureus (MRSA), Hospital-Acquired Pneumonia, Sepsis, and Mediastinitis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Papanicolaou's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile